Research
Hormonal
Menopause is associated with a substantial decrease in endogenous oestrogen concentrations and alterations in body weight, adipose tissue distribution, and energy expenditure, which can predispose women to the development of type 2 diabetes mellitus (T2DM).
Practitioners should be aware of the increased risk of T2DM in menopausal women due to hormonal changes.
StrongSupportsmedium confidence
Menopause...is characterized by substantial decrease in the endogenous oestrogen concentrations and it is accompanied by alterations in body weight, adipose tissue distribution and energy expenditure...that can predispose to the development of T2DM.
Why this rating
The claim is supported by a review of current evidence.
Source
Diabetes in Menopause: Risks and Management
Stavroula Α. Paschou et al. · Current Vascular Pharmacology · 2018
DOI 10.2174/1570161116666180625124405
reviewCited 63×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →